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The first World Congress on Tourette Syndrome and Tic Disorders was held in
London, June 2016 by the Tourette Association of America, Tourettes Action (UK),
and the European Society for the Study of Tourette Syndrome. Presentations arising
from large-scale collaborative projects were an important component of the scientific
programme. This article focuses on areas raised in the hot topics session and two
moderated debates, which covered emerging research in etiology and treatment. The hot
topics ranged across genetics, arguably including the first confirmed Tourette Syndrome
(TS) susceptibility gene NRXN1, neurocognition, and neurophysiology, including the
possibility of a neurocognitive endophenotype for TS and the use of depth and cortical
surface electrodes to investigate the neurophysiology of tics on the background of the
evolving field of deep brain stimulation (DBS), to novel treatment approaches such as
dental orthotics and an online behavioral intervention. The debates aired controversies
in treatment; pharmacotherapy vs. behavioral treatment and the place of medical
cannabinoids. These sessions demonstrate the vibrancy of a field that has considerably
expanded in the last decade, the significant progress that has been made, and the
direction that some of the most fruitful next phases of research will take.
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INTRODUCTION
These sessions of the congress were devoted to late-breaking studies and hot topics, including
controversies in the field of Tourette Syndrome (TS) research or treatment. The presentations fell
into two main themes, the first, elucidating the etiology of TS, and the second, the identification
of novel or controversial treatments for TS. These presentations highlight the importance of
large-scale collaborative efforts in the study of TS and provide evidence that, after many years of
incremental advances, with collaborative efforts more substantial discoveries may be just around
the corner. This is best illustrated in the genetic studies, where nearly 100 clinicians and scientists
contributed clinical samples and expertise, and in the studies of environmental risk factors, which
took place using the Avon Longitudinal Study of Parents and Children (ALSPAC; Golding et al.,
2001), a birth cohort in which data has been collected, curated, and studied for over 20 years by
hundreds of researchers. Such large scale, collaborative efforts are also becoming the norm for
studies examining the efficacy and safety of TS treatments, whether in the form of meta-analyses of
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multiple small investigator-initiated studies, or in the form of
large, multi-institution investigations of a specific treatment.
TS has long been known to be a complex disorder etiologically,
with both genetic and non-genetic contributors. However, clear
specific risk factors for TS, either genetic or environmental, have
been difficult to identify and/or replicate. The availability of
large samples of individuals with extensive phenotype and/or
genotype data, some population-based, and some clinically
ascertained, have recently led to advances in our understanding
of the causes of TS. Although, TS is one of the most heritable
of the neurodevelopmental disorders (Pauls et al., 2014b),
with heritability estimates of 60–80% (Davis et al., 2013), the
last 30 years of genetic studies, including recent genome-
wide association studies, have been inconclusive. These studies
indicate that TS is highly polygenic; that is, hundreds (or perhaps
thousands) of genes of small effect contribute to TS risk in an
additive manner. For this reason, tens of thousands of samples
will likely be needed to identify individual TS susceptibility
variants using genome-wide approaches. However, the currently
available sample sizes, while falling short of what is needed
for comprehensive identification of the genes and gene variants
responsible for TS, may be efficiently used for gene discovery
using alternative approaches.
Genetic Studies
Two presentations in this session focused on such alternative
approaches to dissecting the genetic etiology of TS, and
demonstrate the value of complementary scientific approaches.
In the first, Alden Huang (University of California, Los
Angeles), working with the Tourette Syndrome Association
International Consortium for Genetics (TSAICG), examined the
relationship between TS and copy number variants (CNVs) in
2764 individuals with TS and 2853 ethnically matched controls.
Analyses were limited to large (>400 kilobases), rare (<1%
prevalence) CNVs, which are likely to be pathogenic. Huang
identified multiple recurrent CNVs in genomic regions that
have been previously implicated for TS, as well as substantial
overlap with CNV regions that have been implicated in
other neurodevelopmental disorders, including autism spectrum
disorders (ASD) and intellectual disability(Grayton et al., 2012).
Two of these regions showed an enrichment of CNVs in TS cases
compared to controls. These wereNRXN1 (1-sided Fisher’s exact,
p = 0.007), which has been previously reported to be associated
with TS and CNTN4 (p = 0.029). All of the CNVs detected
in NRXN1 were deletions, consistent with the prior literature
(Nag et al., 2013; McGrath et al., 2014), while both deletions
and duplications were present in the CNTN4 locus. At the time
of the Congress NRXN1 may be considered the first confirmed
susceptibility gene for TS.
The second study used the same dataset to conduct gene
pathway analyses. There are many forms of pathway analyses,
but the basic idea is to identify enrichment of genetic variants
within specific known gene pathways or gene sets. Like the
CNV analyses discussed above, an advantage of pathway
analyses is that they can be effective in relatively small
sample sizes, typically requiring thousands rather than tens of
thousands of samples. This work was conducted by Fotis Tsetsos
(University of Thrace), in conjunction with the TSAICG. Tsetsos
used two complementary statistical approaches to examine
relationships between TS and gene pathways defined from
multiple sources, including curated gene sets from the published
literature, computational gene sets defined from cancer-oriented
microarray data, genes annotated using the same GO search
terms, genes that share a microRNA binding motif, etc. Variants
associated with nervous system tissues, in particular, parietal
cortex and basal ganglia, were enriched in these analyses. A gene
set with promotor regions around TCF3 (transcription factor 3)
was also implicated in TS etiology (corrected p= 0.006). TCF3 is
a member of the HLH (helix-loop-helix) family of transcription
factors, and is thought to regulate developmental patterning
processes in the central nervous system. TCF3 also suppresses
Wnt, a protein that is involved in neuronal differentiation and
proliferation of neural development cells (Gribble et al., 2009).
Studies of Non-genetic Risk Factors
Genetic causation accounts for ∼60% of TS risk, suggesting
that other, non-genetic (environmental) factors are also very
important in the development of this disorder. Previous work
in both clinical and population-based samples have implicated
a number of pre- and perinatal risk factors for TS, including
prenatal maternal smoking, prenatal maternal alcohol use, and
possibly maternal parity and weight gain during pregnancy
(Mathews et al., 2006, 2014; Pringsheim et al., 2009; Motlagh
et al., 2010). In the third study in this session to focus on the
etiology of TS, Yoav Ben-Shlomo (University of Bristol), and
his colleagues used the ALSPAC sample to examine another
type of potential environmental risk factor for TS, maternal
anxiety and depression during pregnancy. The ALSPAC cohort
is a prospective pre-birth cohort that has followed children born
in Avon, UK in 1992 and their parents for over 20 years, and
has collected extensive phenotypic data (Golding et al., 2001).
Ben-Shlomo compared self-reported anxiety and depressive
symptoms for both mothers and fathers at four time points, two
prenatal (18 and 32 weeks), and two postnatal (18 weeks and
8 months after delivery) for children with chronic tic disorders
including TS (TS/CT) and a control sample of children without
chronic tics (Ben-Shlomo et al., 2016). Socioeconomic measures
and other relevant potential confounders were controlled for in
the analysis. After correction for potential confounders, chronic
maternal anxiety (present both pre- and post-birth) and pre-natal
maternal depression (but not post-natal maternal depression)
were significantly associated with TS/CT (odds ratio = 2.17,
p = 0.007; odds ratio 1.86, p = 0.04, respectively). Paternal
anxiety and depression were not significantly associated with
TS/CT. These findings suggest that maternal psychopathology
may be a risk factor for TS and other chronic tic disorders.
Maternal chronic anxiety may in fact represent a shared genetic
susceptibility for TS, as this variable was associated with TS/CT
both pre-and post-natally. In contrast, maternal depression
may represent a time-specific environmental risk factor for
TS, perhaps representing medication use during pregnancy,
or intra-uterine neuroendocrine effects of stress. It should be
noted, however, that both associations require confirmation in
independent datasets.
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The final study pertaining to the etiology of TS in this
session was a systematic review focused on neurocognitive
performance in individuals with TS. This study contributes
to a growing literature on potential endophenotypes for TS
and other complex disorders. An endophenotype is a heritable,
measurable trait or feature that is associated with a disorder of
interest, but is state independent (e.g., manifests in individuals
whether or not they are manifesting the disorder, including
in unaffected family members). No endophenotypes have yet
been identified for TS, but specific neurocognitive abnormalities
have been suggested as potential endophenotypes for two related
disorders that are highly comorbid with TS, obsessive compulsive
disorder (OCD; Pauls et al., 2014a), and attention deficit
hyperactivity disorder (ADHD; Pineda et al., 2011; Eddy and
Cavanna, 2014; Peskin et al., 2015). The study by Beth Hobson
(University of Birmingham), and her colleagues, takes the first
step in identifying potential TS endophenotypes by investigating
whether neurocognitive dysfunction is consistently associated
with TS. A search of PubMed, Medline, and PsychINFO
identified 12 relevant studies, four of which included children
and/or adolescents. In general no consistent differences in
neurocognitive function between TS cases and controls were
found. The one possible exception was in the area of cognitive
inhibitory control. Individuals with TS showed a trend toward
verbal inhibitory deficits, although this finding did not reach the
level of statistical significance. Inhibitory control in TS, typically
motor inhibition, but also cognitive inhibition, may lie at the
heart of the neurology of TS and is an active area of investigation
requiring future study.
TREATMENT
Management of TS is challenging and has remained largely
unsatisfactory through the last decade of intensifying clinical and
scientific interest in the condition. In clinical terms, given the
spectrum nature of the presentation, it is important to define the
treatment target in each case, as comorbidities such as ADHD or
OCD are commonly more impairing than are the tics themselves.
Tics often improve over the course of adolescence and at present
their treatment is overall less reliable and less evidence based than
treatments for the commonly co-occurring disorders. However,
tics can be extremely severe in up to 15% of cases, and their
effect on functioning varies greatly between individuals. Where
tics are severe or intrusive, pharmacotherapy can be considered.
The index drug was haloperidol in the 1950s, and since then
a variety of neuroleptics have been used, including newer or
atypical agents (Hartmann and Worbe, 2013). The dopamine
hypothesis as a substrate for TS essentially originated from
this clinical association and has been variably substantiated in
more recent functional imaging and other work (Singer et al.,
1982; Segura and Strafella, 2013). An alpha-2 adrenergic agonist,
clonidine, is well-established and other classes of drugs with some
support for efficacy in TS treatment include the anticonvulsant
Topiramate and the dopamine depleter tetrabenazine. Treatment
efficacy for each option is variable. There is relatively little
randomized controlled data, sparse head-to-head comparisons,
and the available Class 1 evidence needs to be considered in
the context of generally short-term trials conducted over the
course of only weeks in a condition that is hard to objectively
measure and naturally fluctuates, whereas in clinical practice an
initial positive response with less benefit over time is commonly
seen. There are several reviews and recommendations for drug
treatment and the first truly systematic review and meta-analysis
is in press (Roessner et al., 2011; Hollis et al., 2016).
The other conventional modality of treatment is behavioral.
These have evolved from the early exploratory literature into
evidence-based schedules based around strategies either designed
to suppress tics by using competing responses to premonitory
urges that precede tics (e.g., Habit Reversal Training; HRT) or to
increase tolerance of the premonitory urges (e.g., Exposure with
Response Prevention; ERP). HRT has been incorporated into a
package called Comprehensive Behavioral Intervention for Tics
(CBIT) which was effective in both children and adults in two
influential randomized trials of 10 weeks therapy followed up for
6 months (Wilhelm et al., 2012).
In addition to the conventional treatments of
pharmacotherapy and behavioral therapy, alternative approaches
are also evolving, ranging from neurosurgical stereotactic deep
brain stimulation (DBS), which has some evidence base, although
not yet extensive, and other more controversial possibilities, such
as oral orthotic devices and the use of medical cannabinoids.
The treatment talks in this session focused on (1) the more
controversial approaches to treating tics and (2) alternative
approaches to delivering the more conventional treatments.
John Walkup (Cornell Weill Medical Center), presented the
methodology and preliminary results from a TSA sponsored
study of an oral orthotic device (an occlusal splint). This
treatment evolved out of observations from the dental
community that dental orthotics reduce tics anecdotally, with an
underlying hypothesis that TS is caused by a brainstem response
to dental factors rather than being a genetic neurodevelopmental
syndrome (Sims and Stack, 2009). This hypothesis and
corresponding treatment approach did not gain initial traction
amongst neuropsychiatrists. However, patients and parents in
a number of countries have been willing to try occlusal splints,
sometimes at significant expense, leading to a real need for a
high quality clinical trial. Walkup presented a double blind
placebo controlled randomized study using the occlusal splint
compared to sham orthotics over 2 weeks, with assessment of
durability of effect over a further 4–6 weeks. Outcome measures
include changes in tic severity, improvement in functioning, and
assessments of acceptability and patient satisfaction. To date,
open-label pilot studies of the intervention have found it to be
feasible, acceptable and non-harmful. The first three participants
had high satisfaction despite mild to moderate adverse effects
(sore mouth, excess salivation etc.) and had reduced tic
severity with two participants being very much improved
on measures of functioning for the initial 2 weeks, although
benefit was not sustained at this level for the remaining 4–6
weeks.
Michael Himle (University of Utah), presented the
development of “TicHelper,” a self-administered online tool
for teaching or delivering CBIT from the team that have
developed the treatment. If this mode of delivery is successful,
there would be immediate potential impact on clinical practice,
as specialist psychology resources are limited in most countries,
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particularly in non-urban areas, so that behavioral therapy often
cannot be delivered. In a pilot study, the investigators selected 8
children to use the program for 2 weeks to target a single tic. 7/8
children showed a much increased awareness of tics and were
able to demonstrate appropriate use of a competing response,
all important components of successful CBIT. Longer term
outcomes, including durable improvement of tics, are not yet
available.
As noted previously, efforts are underway to understand the
neurophysiology and etiology of TS, but much more work is yet
to be done. Understanding the neurophysiology of the generation
and control of tics and their neural correlates is relevant to
identifying and refining appropriate treatments for this complex
disorder. This is well-illustrated in the continuing questions over
the most effective surgical target for DBS, the most radical of
the existing treatments for TS, and the selection of patients
likely to benefit. Non-invasive data mapping the neurological
substrate for TS is available from functional radioisotope and
magnetic resonance imaging and at an altogether different
temporal and anatomical resolution by recording from DBS
electrodes (Bour et al., 2015). On behalf of Shute et al.,
Aysegul Gunduz (University of Florida) presented a unique study
examining two patients who were implanted with both subdural
electrodes (primary motor, M1, and premotor, PM cortices) and
depth electrodes (thalamic centromedian nucleus, Cm). Awake
recordings were made of local field potentials (thalamus) and
electrocorticograms (cortex) with the patient ticcing, suppressing
tics, making voluntary movements, and imitating tics. Regionally
specific activation patterns were suggested by phase amplitude
coupling analysis (PAC). A dissociation was found between
ticcing in which contralateral low frequency activity in all three
areas was seen and for voluntary movements in which only
the cortex was active. In one patient, tics could be detected
electrophysiologically using this approach with 70% sensitivity
and specificity. This complements the better established field of
PAC changes in Parkinson’s disease and its treatment with DBS
and also opens further possibilities for capture and treatment
of tics within closed loop adaptive DBS systems (Almeida et al.,
2015).
Controversies in Treatment
In addition to the scientific presentations, the two congress
debate sessions focused on treatment, and in particular,
on controversies in treatment. The first explored CBIT vs.
pharmacotherapy as first line treatment, and was chaired
by Stanley Fahn (Columbia University), and presented
by Douglas Woods (Texas A & M University; advocating
CBIT) and Donald Gilbert (Cincinnati Children’s Medical
Center; advocating pharmacotherapy). Like all good
conference debates, fair amounts of devil’s advocacy and
inventiveness were employed, reflecting the underlying
truths that all clinicians are grappling with- drugs are not
as reliably effective as we would like and commonly cause
adverse effects (usually mild), CBIT and other behavioral
interventions are not as accessible as they should be due
to lack of funding and experienced practitioners within
local reach. An important point that was raised during the
debate was the fact that there are no comparative studies of
the two modalities of treatment, and that such studies are
necessary.
The other topic was the use of cannabinoids (including
marijuana) in the treatment of TS, and was chaired by Joseph
Jankovic (Baylor College of Medicine) and energetically debated
by Kirsten Mueller-Vahl (Hannover School of Medicine;
representing the pro-cannabinoid stance), and Paul Sandor
(University of Toronto; representing the anti-cannabinoid
stance). The underlying hypothesis was that neurotransmitters
other than dopamine, including endocannabinoids, are
likely to be important substrates of various aspects of TS.
Endocannabinoids are thought to modulate many other
classes of neurotransmitter, including monoamines with a
high density of CB1 receptors in the basal ganglia. There
are limited case reports and two controlled trials of Delta
9-tetrahydrocannabinol (THC; Muller-Vahl et al., 2002, 2003)
which followed single dose studies. However, a comprehensive
Cochrane review concluded there is insufficient evidence
for clinical use (Curtis et al., 2009). As with the other
controversial treatments, this area is worthy of further
study. In clinical practice it is uncommon for adults in the
UK to self-medicate with marijuana despite fairly frequent
recreational use, which is in contrast to a German interview
study (Muller-Vahl et al., 1997). Use of the medically isolated
component of THC may offer different or more reliable effects,
perhaps within the usual context of drug treatment of TS in
which efficacy of all evidence-based options varies between
individuals.
CONCLUSIONS AND FUTURE
DIRECTIONS
As can be seen in the work presented in this session,
research on the causes and treatment of TS is at a turning
point. While much progress has been made in the last 10
years, there is still much to be done. In order to make
substantial progress, collaboration is required, not only between
investigators in similar fields, but also between scientists and
clinicians across disciplines, and between scientists, clinicians,
advocacy groups, and patients and families. Such collaborative
efforts have been enormously successful in propelling forward
breakthroughs in identifying genetic causes of ASD, new and
novel treatments for cancer, to name two of many examples.
Only with broad support and participation within and across
constituencies, as well as a willingness to take risks, will
we be able to make real strides forward toward a better
understanding of this disorder, and toward effective identification
and treatments.
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